Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.235 USD | -10.96% | -8.16% | -46.77% |
03:34pm | Leerink Partners Downgrades CureVac to Market Perform From Outperform, Sets Price Target at $4 | MT |
Apr. 24 | CureVac Begins Early Stage Portion of Investigational Vaccine Trial | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-46.77% | 562M | |
+0.55% | 43.84B | |
+5.43% | 41.68B | |
+45.26% | 41.25B | |
-11.96% | 27.04B | |
+6.26% | 25.53B | |
-24.52% | 18.18B | |
-3.36% | 12.29B | |
+26.09% | 12.29B | |
+6.64% | 11.15B |
- Stock Market
- Equities
- CVAC Stock
- News CureVac N.V.
- CureVac N : Guggenheim Initiates CureVac at Buy